We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
The current global market of prefilled syringes is comprised of over two billion units per year and growing. Many chronic diseases, such as multiple sclerosis and rheumatoid arthritis, require home-based administration of injectable therapies.
Auto-injectors that include a glass syringe have been a safe and convenient delivery system, but they have notable limitations, including:
Any glass product runs the risk of breakage, which can lead to particulate contamination. Particulate contamination is the unintended presence of extraneous, mobile and/or undissolved particles in a therapy or parenteral solution. These particles can be of various sizes, usually only detectable by visual inspection in general greater than or equal to 50 Um or sub-visible with a range of 2-50 um, demanding specific analytical tests for their detection. Particulate contamination may cause inflammation, which can affect a patient’s brain, eyes, lungs, liver, heart, intestines, kidneys and spleen.
Cyclic olefin polymers, such as Daikyo Crystal Zenith® (CZ), may provide a better patient risk profile and drug delivery system. This highly break resistant material can help to avoid the issues of particulate contamination and glass breakage. The material also forms an excellent moisture barrier, which helps to ensure extremely low particulate levels.
The Daikyo Crystal Zenith syringe with the FluroTec® barrier film-coated piston may eliminate the risk of delays and patient safety issues that are the unintended consequences of traditional combination delivery products in use today.
For more information about the CZ syringe or other injectable solutions from West, visit our website.
<p>Tibor Hlobik, Director, Prefillable Solutions and Technologies<br />Mike Gills, Customer Technical Support Process Engineer</p><p>Growth in biopharmaceutical therapeutics is leading innovation with prefillable syringe systems. These complex sensitive drug products require highly inert primary packaging materials for improved stability and delivery in perfect quality for reduced safety risk. This <span style="text-decoration: underline; color: #0000ff;"><a href="https://www.westpharma.com/west-login">poster</a></span> will provide a quality comparison of primary prefillable syringe options including glass, coatings/laminates and cyclic olefin polymers, and highlight the findings of a case study comparing 1mL long syringe attributes.</p>
In an effort to treat more complex diseases, the injectables market has seen high-value molecules dominate clinical pipelines. As modern molecules continue to gain market share, it is becoming the norm for drug manufacturers to plan containment system compatibility earlier in their drug development process due to the sensitivities of their complex molecules. With packaging systems becoming an integral part of the drug development and research process, a challenge drug manufacturers face is the plentitude of choice.
It is an exciting time to be in the Cell and Gene therapy industry. The astounding growth and development we have witnessed in the cell & gene therapy industry over the last decade is bringing life-changing therapies to the patients who have been so anxiously awaiting them. <br /><br />At the same time, as with any new drug class, challenges that may not have been considered during the drug development phase may suddenly show up and stand in the way of overcoming that last hurdle: Packaging and delivering your precious new molecule to the patient.
The global injectable drug market sees an ever-increasing adoption of high-value biologic drug products. More than half of today’s 20 top selling injectables are biologics, and many of them are delivered in a prefilled syringe. Even though glass syringes are predominantly used for primary containment of parenterals, the (bio)pharmaceutical industry continues to cope with certain limitations associated with glass prefilled systems.
<p><span>Anti-VEGF therapeutics for the treatment of ophthalmic conditions such as neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME) have significantly improved patient prognoses, in some cases preventing or reversing progression to blindness. Routine injections into the eye of recombinant protein drugs such as bevacizumab, ranibizumab or aflibercept have proven to be efficacious in neutralizing the binding of over-expressed vascular endothelial growth factor (VEGF) proteins to their corresponding cellular receptors, thus interrupting the angiogenesis signaling pathway which otherwise leads to the disease states. In short, anti-VEGF injections are preventing or restoring vision loss for millions of people world-wide.</span></p>
English
Chinese
